Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution

References

• AhujaMDhakeASSharmaSKMajumdarDKTopical Ocular Delivery of NSAIDsAAPS J2008425
   Web of Science ®Google Scholar
• McColginAZHeierJSControl of intraocular inflammation associated with cataract surgeryCurr Opin Ophthalmol2000113610724825
   PubMed Web of Science ®Google Scholar
• PerryHDDonnenfeldEDAn update on the use of ophthalmic ketorolac tromethamine 0.4%Expert Opin Pharmacother2006719910716370927
   PubMed Web of Science ®Google Scholar
• ChangJHChungHNon-steroidal anti-inflammatory drug and endotoxin induced unveitisKorean J Ophthalmol1993735428189632
   PubMedGoogle Scholar
• PolanskyJRWeinrebRNSteroids as anti-inflammatory agentsPharmacology of the EyeSearsMLSpringer-VerlagNew York1984460538
   Google Scholar
• CampbellWBHalushkaPVLipid-derived autacoids: eicosanoids and platelet-activating factorHardmanJGLimbirdLEMolinoffPBGoodman and Gilman’s The Pharmacological Basis of Therapeutics9th edNew York, NYMcGraw-NetHill1996601616
   Google Scholar
• DonnenfeldEDDonnenfeldAGlobal experience with Xibrom (bromfenac ophthalmic solution) 0.09%: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drugInt Ophthalmol Clin2006464214017060789
   PubMedGoogle Scholar
• OkaTShearerTRAzumaMInvolvement of cyclooxygenase-2 in rat models of conjunctivitisCurr Eye Res200429273415370364
   PubMed Web of Science ®Google Scholar
• McGheeCNDeanSDanesh-MeyerHLocally administered ocular corticosteroids: benefits and risksDrug Saf200225335511820911
   PubMed Web of Science ®Google Scholar
• SamiyNFosterCSThe role of non-steroidal anti-inflammatory drugs in ocular inflammationInt Ophthalmol Clin1996361952068778065
   PubMedGoogle Scholar
• FlachAJTopical nonsteroidal anti-inflammatory drugs in ophthalmologyInt Ophtalmol Clin200242111
   PubMedGoogle Scholar
• RojanasakulYRobinsonJRTransport mechanisms of the cornea: characterization of barrier permselectivityInt J Pharm198955237246
   Web of Science ®Google Scholar
• SchalnusRTopical nonsteroidal anti-inflammatory therapy in ophthalmologyOphthalmologica2003217899812592044
   PubMed Web of Science ®Google Scholar
• GuptaMMajumdarDKEffect of concentration, pH and preservatives on in vitro transcorneal permeation of ibuprofen and flurbiprofen from non-buffered aqueous dropsIndian J Exp Biol1997358448499475059
   PubMedGoogle Scholar
• AhujaMDhakeASMajumdarDKEffect of formulation factors on in vitro permeation of diclofenac from experimental and marketed aqueous eye drops through excised goat corneaYakugaku Zasshi20061261369137517139162
   PubMed Web of Science ®Google Scholar
• Voltaren Ophthalma^® (diclofenac) [package insert]Duluth, GANovartis Ophthalmics2003
   Google Scholar
• Acular^® (ketorolac) [package insert]Irvine, CAAllergan Inc2002
   Google Scholar
• Nevanac^® (nepafenac) [package insert]Fort WorthAlcon Laboratories2005
   Google Scholar
• Xibrom^® (bromfenac) [package insert]Irvine, CAISTA Pharmaceuticals, Inc2006
   Google Scholar
• O’BrienTPEmerging guidelines for the use of NSAID therapy to optimize cataract surgery and patient careCurr Med Res Opin2005211131113716004683
   PubMed Web of Science ®Google Scholar
• HeierJSToppingTMBaumannWKetorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edemaOphthalmology20001072034203911054327
   PubMed Web of Science ®Google Scholar
• RobertsCWBrennanKMA comparison of topical dicolfenac with prednisolone for postcataract inflammationArch Ophthal19951137257277786212
   PubMed Web of Science ®Google Scholar
• El-HaraziSMRuizRSFeldmanRMA randomized double-masked trial comparing ketorolac tromethamine 0.5%, diclofenac sodium 0.1%, and prednisolone acetate 1% in reducing post-phacoemulsification flare and cellsOphthalmic Surg Lasers1998295395449674003
   PubMedGoogle Scholar
• FlachAJNonsteroidal anti-inflammatory drugsTasmanWDuane’s foundations of clinical ophthalmologyPhiladelphia (PA)Lippincott1994132
   Google Scholar
• WolfEJBraunsteinAShihCBraunsteinREIncidence of visually significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepafenacJ Cataract Refract Surg200793391546154917720068
   PubMed Web of Science ®Google Scholar
• HsuJKJohnstonWTReadRWHistopathology of corneal melting associated with diclofenac use after refractive surgeryJ Cataract Refract Surg20032925025612648633
   PubMed Web of Science ®Google Scholar
• KeT-LGraffGSpellmanJMYanniJMNepafenac a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriersInflammation20002437138410850858
   PubMed Web of Science ®Google Scholar
• BrownHBTaylorPMuscarinic receptor agonists and antagonistsHardmanJGLimbirdLEMolinoffPBRuddonRWGoodman and Gilman’s The Pharmacological Basis of Therapeutics9th edNew YorkMcGraw-Hill1996141160
   Google Scholar
• SancilioLFNolanJCWagnerLEWardJWThe analgesic and anti-inflammatory activity and pharmacologic properties of bromfenacArzneimittelforschung1987375135193497637
   PubMed Web of Science ®Google Scholar
• WalshDAMoranHWShambleeDAAntiinflammatory agents. 3. Synthesis and pharmacological evaluation of 2-amino-3-benzoylpheylacetic acid and analoguesJ Med Chem198427137913886436487
   PubMed Web of Science ®Google Scholar
• Data on file. ISTA Pharmaceuticals, Inc.
   Google Scholar
• WaterburyLDSillimanDJolasTComparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodiumCurr Med Res Opin2006221133114016846546
   PubMed Web of Science ®Google Scholar
• YanniJMGraffGHellbergMRTopically administrable compositions containing 3-benzoylphenylaceteic acid derivatives for treatment of ophthalmic inflammatory disorders. Alcon Laboratories, Inc., assignee. US Patent 5,475,034. December 12, 1995.
   Google Scholar
• OgawaTMiyakeKMcNamaraTRPharmacokinetic profile of topically applied bromfenac sodium ophthalmic sodium ophthalmic solution 0.1% in subjects undergoing cataract surgeryProceedings of the Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingFt. Lauderdale, FLApril 30–May 4, 2006A687
   Google Scholar
• BakalyanGADeshmukhHMPattersonHConcentrations of radioactivity in ocular tissues after a single topical dose of Cbromfenac ophthalmic solutionProceedings of the American Society of Cataract and Refractive Surgery (ASCRS) MeetingSan Francisco, CAMarch 17–22, 2006Abstract p. 227.
   Google Scholar
• HelbergMRNixonJCUse of non-steroidal anti-inflammatory agents in combination with compounds that have PF prostaglandin agonist activity to treat glaucoma and ocular hypertension. Alcon Laboratories, Inc., assignee. US Patent 6,342,524 B1. January 29, 2002.
   Google Scholar
• McNamaraTRBaklayanGADeshmukhHMConcentrations of radioactivity in ocular tissues after a single 0.09% topical dose of C-bromfenac ophthalmic solutionProceedings of the Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingFt. Lauderdale, FLApril 30–May 4, 2006A687
   Google Scholar
• MasudaKFukadoYShimizuHEffect of bromfenac sodium ophthalmic solution on inflammation following intraocular lens implantationGanka Rinsho Iho (Jpn Rec Vin Ophthalmol)199791745750
   Google Scholar
• WaltersTRaizmanMErnestPGaytonJLehmannRIn vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenacJ Cataract Refract Surg20073391539154517720067
   PubMed Web of Science ®Google Scholar
• BucciFWaterburyDComparison of ketorolac 0.4% and bromfenac 0.09% at trough dosing: Aqueous drug absorption and prostaglandin E2 levelsJ Cataract Refract Surg2008341509151218721711
   PubMed Web of Science ®Google Scholar
• KawaguchiTKidaTNemotoSEffect of bromfenac ophthalmic solution on ocular inflammation and corneal epithelial barrier function following cataract surgeryFolia Ophthalmol Jpn200354276279
   Google Scholar
• TakamatsuFShiroyamaNSaitoYEfficacy and adverse effects of bromfenac ophthalmic solution following cataract surgery. Rinsho Ganka(Jpn J Clin Ophthalmol)20035712331237
   Google Scholar
• OharaKOhkubaAMiyamotoTEffect of bromfenac sodium on postoperative inflammationJpn J Catarac Refract Surg200418112
   Google Scholar
• DonnenfeldEDHollandEJStewartRHGowJAGrilloneLRBromfenac Ophthalmic Solution 0.09% (Xibrom) Study GroupBromfenac ophthalmic solution 0.09% (Xibrom) for postoperative ocular pain and inflammationOphthalmology200711491653166217445902
   PubMed Web of Science ®Google Scholar
• StewartRHGrilloneLRShiffmanMLDonnenfeldEDGowJABromfenac Ophthalmic Solution 0.09% Study GroupThe systemic safety of bromfenac ophthalmic solution 0.09%J Ocul Pharmacol Ther200723660161218001250
   PubMed Web of Science ®Google Scholar
• GreavesRRAgarwalAPatchDInadvertent diclofenac rechallenge from generic and non-generic prescribing, leading to liver transplantation for fulminant liver failureEur J Gastroenterol Hepatol200113717311204815
   PubMed Web of Science ®Google Scholar
• AithalGPDiclofenac-induced liver injury: A paradigm of idiosyncratic drug toxicityExp Opin Drug Saf20043519523
   PubMedGoogle Scholar
• MacarioALipmanAGKetorolac in the era of cyclo-oxygenase-2 selective nonsteroidal anti-inflammatory drugs: A systematic review of efficacy, side effects, and regulatory issuesPain Med2001233635115102238
   PubMed Web of Science ®Google Scholar
• WaterburyLDMarked contralateral activity of bromfenac in a rabbit model of ocular inflammationInvest Ophthalmol Vis Sci200546: Abstract 3936.
   Web of Science ®Google Scholar
• National PBM Drug Monograph, Bromfenac 0.09% Ophthalmic Solution (Xibrom®) June 2006. Available from: http://www.pbm.va.gov/monograph/Bromfenac0.09PercentOphthalmicSolution.pdf
   Google Scholar
• LinJCRapuanoCJLaibsonPRCorneal melting associated with use of topical nonsteroidal anti-inflammatory drugs after ocular surgeryArch Ophthalmol20001181129113210922213
   PubMed Web of Science ®Google Scholar
• CongdonNGScheinODvon KulajtaPCorneal complications associated with topical ophthalmic use of nonsteroidal anti-inflammatory drugsJ Cataract Refract Surg20012762263111311634
   PubMed Web of Science ®Google Scholar
• FlachAJCorneal melts associated with topically applied non-steroidal anti-inflammatory drugsTrans Am Ophthamol Soc200199205212
   PubMedGoogle Scholar
• GuideraACLuchsJIUdellIJKeratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugsOphthalmology200110893694411320025
   PubMed Web of Science ®Google Scholar
• MianSIGuptaAPinedaRIICorneal ulceration and perforation with ketorolac tromethamine (Acular) use after PRKCornea20062523223416371790
   PubMed Web of Science ®Google Scholar
• WolfEJKleimanLZSchrierANepafenac-associated corneal meltJ Cataract Refract Surg200733111974197517964407
   PubMed Web of Science ®Google Scholar
• AsaiTNakagamiTMochizukiMThree cases of corneal melting after instillation of a new nonsteroidal anti-inflammatory drugCornea20062522422716371788
   PubMed Web of Science ®Google Scholar
• IsawiHDhaliwalDKCorneal melting and perforation in Stevens Johnson syndrome following topical bromfenac useJ Cataract Refract Surg20073391644164617720085
   PubMed Web of Science ®Google Scholar
• HashizumeNSaikaSOkadaYEffects of anti-inflammatory drugs on migration of the rabbit corneal epitheliumJ Cataract Rrefract Surg20012714991502
   Web of Science ®Google Scholar
• HershPSRiceBABaerJCTopical nonsteroidal agents and corneal would healingArch Ophthalmol19901085775832322160
   PubMed Web of Science ®Google Scholar
• KitaoNShimojiHFukudaMPostmarketing surveillance of bromfenac sodium (Bronuck) ophthalmic solutionJn Eye20052212991308
   Google Scholar
• TaylorSAGalbraithSMMillsRPCauses of non-compliance with drug regimens in glaucoma patients: a qualitative studyJ Ocul Pharmacol Ther20021840140912419091
   PubMed Web of Science ®Google Scholar
• PatelSCSpaethGLCompliance in subjects prescribed eye drops for glaucomaOphthalmic Surg1995262332367651690
   PubMedGoogle Scholar
• ChaSHLeeJSOumBSKimCDCorneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitroClin Experiment Ophthalmol20043218018415068436
   PubMed Web of Science ®Google Scholar
• FlachAJCyclooxygenase inhibitors in ophthalmologySurv Ophthalmol1992Jan–Feb3642592841549810
   PubMed Web of Science ®Google Scholar
• FlachAJThe incidence, pathogenesis, and treatment of cystoids macular edema following cataract surgeryTrans Am Ophthalmol Soc19989655763410360304
   PubMedGoogle Scholar
• QuinnCJCystoid macular edemaOptom Clin1996511111308963073
   PubMedGoogle Scholar
• TranosPGWickremasingheSSStangosNTTopouzisFTsinopoulosIPavesioCEMacular edemaSurvev Ophthalmol200449470490
   PubMed Web of Science ®Google Scholar
• ColinJThe role of NSAIDs in the management of postoperative ophthalmic inflammationDrugs20076791291130817547472
   PubMed Web of Science ®Google Scholar
• RobertsCWPretreatment with topical diclofenac sodium to decrease postoperative inflammationOphthalmology19961036366398618764
   PubMed Web of Science ®Google Scholar
• RaySD’AmicoDJPseudophakic macular edemaSemin Ophthalmol20021716718012759847
   PubMedGoogle Scholar
• UrsellPGSpaltonDJWhitcupSMNussenblattRBCystoid macular edema after phacoemulsification: relationship to blood-aqueous barrier damage and visual acuityJ Cataract Refract Surg199925111492149710569164
   PubMed Web of Science ®Google Scholar
• MentesJErakgunTAfrashiFKerciGIncidence of cystoids macular edema after uncomplicated phacoemulsificationOphthalmologica2003217640841214573973
   PubMed Web of Science ®Google Scholar
• GulkilikGKocaboraSTaskapiliMEnginGCystoid macular edema after phacoemulsification: risk factors and effect on visual acuityCan J Ophthalmol2006469970317224950
   PubMed Web of Science ®Google Scholar
• SivaprasadSMcCluskeyPLightmanSIntravitreal steroids in the management of macular oedemaActa Ophthalmol Scand20068472273317083528
   PubMedGoogle Scholar
• MiyakeKPrevention of cystoid macular edema after lens extraction by topical indomethacin (I). A preliminary reportGraefes Arch Klin Exp Ophthalmol19772038188
   Web of Science ®Google Scholar
• FlachAJDolanBJIrvineAREffectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edemaAm J Ophthalmol19871034794863551617
   PubMed Web of Science ®Google Scholar
• McColginAZRaizmanMBEfficacy of topical Voltaren in reducing the incidence of postoperative cystoid macular edemaInvest Ophthalmol Vis Sci199940Suppl2899950586
   PubMed Web of Science ®Google Scholar
• GrossJGXibrom (bromfenac) reduces cystoid macular edema associated with vein occlusions, macular epiretinal membrane, diabetic retinopathy and age related macular degenerationPoster F-3 presented at: Annual Meeting of the Retina SocietySeptember 27–30Boston
   Google Scholar
• RhoDSSollSMMarkovitzBJBromfenac 0.09% versus diclofenac sodium 0.1% verseus ketorolac tromethamine 0.5% in the treatment of acute pseudophakic cystoids macular edema: diclofenac versus ketorolacProceedings of the Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingFt. Lauderdale, FLApril 30–May 4, 2006AF211
   Google Scholar
• OharaKOhkuboAMiyamotoTPrevention of miosis during cataract surgery by topical bromfenac sodiumRinsho Ganka (Jpn J Clin Ophthalmol)20045813251328
   Google Scholar
• Miyake-KashimaMTakanoYTanakaMComparision of 0.1% bromfenac sodium and 0.1% pemirolast potassium for the treatment of allergic conjunctivitisJpn J Ophthalmol20044858759015592786
   PubMed Web of Science ®Google Scholar
• UsuiMMasudaKEffect of bromfenac sodium (AHR-10282B) eye drops on anterior uveitisGanka Rinsho Iho (J Rev Clin Ophthalmol)1997913944
   Google Scholar
• FitzGeraldGAPatronoCThe coxibs, selective inhibitors of cyclooxygenase-2N Engl J Med2001345643344211496855
   PubMed Web of Science ®Google Scholar